Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

BeiGene logo

About BeiGene Stock (NASDAQ:BGNE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$174.72
$217.22
52-Week Range
N/A
Volume
331,608 shs
Average Volume
336,748 shs
Market Capitalization
$18.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$274.20
Consensus Rating
Buy

Company Overview

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

BGNE Stock Analysis - Frequently Asked Questions

BeiGene, Ltd. (NASDAQ:BGNE) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by $0.04. The business's revenue was up 28.2% on a year-over-year basis.

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that BeiGene investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Saia (SAIA).

Company Calendar

Last Earnings
11/12/2024
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BGNE
CIK
1651308
Fax
N/A
Employees
9,000
Year Founded
2010

Price Target and Rating

High Price Target
$300.00
Low Price Target
$235.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$881.71 million
Net Margins
-25.94%
Pretax Margin
-24.07%
Return on Equity
-25.12%
Return on Assets
-14.95%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
1.93
Quick Ratio
1.72

Sales & Book Value

Annual Sales
$3.32 billion
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$37.10 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
97,618,000
Free Float
90,195,000
Market Cap
$18.03 billion
Optionable
Optionable
Beta
0.57

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:BGNE) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners